| Revenue growth | FY26 revenue ₹270.17 Cr, down 7.7% YoY. |
|---|---|
| Margins | Gross margin improved 80 bps to 44.2% on better mix. |
| Order book | 964 total registered products; 200+ in pipeline. |
| Demand visibility | Strong growth in LATAM; 49 new product registrations secured. |
| Management confidence | High on backward integration and LATAM market diversification. |
Growth
FY26 Consolidated Revenue down 7.7% YoY; PAT fell 94.3% to ₹1.42 Cr; LATAM revenue grew 11% YoY.
Outlook
Received manufacturing license for Hyderabad facility; targeting WHO-GMP certification and deeper penetration in Latin America and Africa.
Risks
Extended working capital cycles in institutional business, particularly in Angola; exit from ancillary Building Hardware business.
Earnings Call filed with NSE, NSE: BALAXI. Summary written with AI assistance from the document.
Balaxi Pharmaceuticals Ltd: key numbers
- Share price
- ₹22.76
- Market cap
- ₹125.7 Cr
- Revenue (annual)
- ₹270.2 Cr
- Net profit (annual)
- ₹1.42 Cr
- P/E (TTM)
- 51.8×Sector 47.4×
- Promoter holding
- 65.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaxi Pharmaceuticals Ltd
All →Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.
Balaxi Pharmaceuticals Business Update
Balaxi Pharmaceuticals has received WHO-GMP certification for its first pharmaceutical formulation manufacturing facility in Telangana. The facility has commenced manufacturing initially approved products for international markets.
Balaxi Pharmaceuticals Management Change
Balaxi Pharmaceuticals Limited shareholders approved the re-appointment of Ms. Akshita Ostwal as an Independent Director for a second five-year term starting September 5, 2026.
Balaxi Pharmaceuticals Annual General Meeting
Balaxi Pharmaceuticals Limited held its 83rd Annual General Meeting on August 24, 2026. Shareholders voted on financial statements and director re-appointments during the proceedings.
Balaxi Pharmaceuticals Investor Presentation: Key Takeaways
Balaxi reported 14.1% YoY revenue growth in Q1 FY27, driven by market diversification and its first proprietary manufacturing facility. Strategy emphasizes backward integration in Latin America and Africa.
Balaxi Pharmaceuticals Q1 FY27 Results: Net Profit ₹1.3 Cr, Up 333.3% YoY
Balaxi Pharmaceuticals Ltd reported revenue from operations of ₹80.7 Cr (+14.1% YoY) and net profit of ₹1.3 Cr (+333.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.3 Cr · +333.3% YoY